Global healthcare company Abbott announced the launch of its latest generation XIENCE Sierra everolimus-eluting coronary stent system in India. This launch comes after the stent system received regulatory approval from India’s Central Drugs Standard Control Organisation (CDSCO) in February 2023.
The XIENCE Sierra is part of Abbott’s family of drug-eluting stents used to treat narrowed coronary arteries caused by coronary artery disease. According to the U.S. FDA, these stent systems consist of a metal stent coated with the drug everolimus and a polymer to control drug release. The stent is delivered and expanded in the narrowed artery via a catheter system.
Tushar Sharma, general manager of Abbott’s vascular business in India and South Asia, highlighted that XIENCE Sierra is being launched to allow physicians to more smoothly deliver the stent even in challenging cases. Cardiovascular disease is the leading cause of mortality from non-communicable diseases in India, with Indians known to have a high prevalence of coronary artery disease at 21.4% for diabetics and 11% for non-diabetics.
Sharma stated “The innovative design and improved delivery will help physicians gain access and unblock difficult-to-treat lesions with more flexibility and precision. With the incidence of coronary artery disease on the rise in India, it’s important for us to provide technologies that help doctors optimally implant stents, so patients have the best outcomes possible.”
Abbott claims the XIENCE Sierra stent has proven efficacy for treating narrowed lesions and complex patient cases, backed by over 120 clinical trials involving 120,000 patients. The improved delivery in implanting the device is expected to allow better stent placement and outcomes for Indian patients suffering from coronary artery disease.
Last updated: December 26th, 2025
